Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of ZK-Epothilone (ZK-Epo; ZK219477) Plus Prednisone as First-line Chemotherapy in Patients With Metastatic Androgen-independent Prostate Cancer

NCT00350051 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00350051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00350051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of ZK-Epothilone (ZK-Epo; ZK219477) Plus Prednisone as First-line Chemotherapy in Patients With Metastatic Androgen-independent Prostate Cancer
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
August 1, 2006
Completion date
December 21, 2009
Enrollment
53 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer